Search

Your search keyword '"Smolen, J."' showing total 1,818 results
Start Over Author "Smolen, J."
1,818 results on '"Smolen, J."'

1. AB0638 DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL

Author

Smolen, J. S., primary, Mikuls, T., additional, Galloway, J., additional, Müller-Ladner, U., additional, Curtis, J. R., additional, Hashimoto, M., additional, Takeuchi, T., additional, Choy, E., additional, Tanaka, Y., additional, Cara, C., additional, Lauwerys, B., additional, Tilt, N., additional, Ufuktepe, B., additional, and Taylor, P. C., additional

Published
2024
Full Text
View/download PDF

2. AB0027 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH INTRAVENOUS EU-APPROVED TOCILIZUMAB AND US-LICENSED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-ARM, SINGLE-DOSE STUDY IN HEALTHY JAPANESE SUBJECTS

Author

Haranaka, M., primary, Eto, T., additional, Tanaka, T., additional, Yazawa, R., additional, Burmester, G. R., additional, Keystone, E., additional, Kim, S. H., additional, Bae, Y., additional, Suh, J., additional, Kim, Y., additional, Lee, J., additional, and Smolen, J. S., additional

Published
2024
Full Text
View/download PDF

4. AB0184 ROLE OF DENDRITIC CELLS IN ARTHRITIS AND OSTEOCLASTOGENESIS

Author

Mazzucato-Puchner, A., primary, Simader, E., additional, Saferding, V., additional, Hofmann, M., additional, Kieler, M., additional, Pfeifle, R., additional, Krönke, G., additional, Smolen, J. S., additional, Hayer, S., additional, Steiner, G., additional, Aletaha, D., additional, and Blüml, S., additional

Published
2024
Full Text
View/download PDF

6. OP0062 EULAR POINTS TO CONSIDER FOR THE DEFINITION OF CLINICAL AND IMAGING FEATURES SUSPICIOUS FOR PROGRESSION TO PSORIATIC ARTHRITIS

Author

Zabotti, A., primary, De Marco, G., additional, Gossec, L., additional, Baraliakos, X., additional, Aletaha, D., additional, Iagnocco, A., additional, Gisondi, P., additional, Balint, P., additional, Bertheussen, H., additional, Boehncke, W. H., additional, Damjanov, N., additional, De Wit, M., additional, Errichetti, E., additional, Marzo-Ortega, H., additional, Protopopov, M., additional, Puig, L., additional, Queiró Silva, R., additional, Ruscitti, P., additional, Savage, L., additional, Schett, G., additional, Siebert, S., additional, Stamm, T., additional, Studenic, P., additional, Tinazzi, I., additional, Van den Bosch, F., additional, Van der Helm – van Mil, A., additional, Watad, A., additional, Smolen, J. S., additional, and Mcgonagle, D., additional

Published
2023
Full Text
View/download PDF

7. AB0056 CYTOKINE-DIRECTED CELLULAR CROSSTALK IMPRINTS SYNOVIAL PATHOTYPES IN RHEUMATOID ARTHRITIS

Author

Kugler, M., primary, Dellinger, M., additional, Kartnig, F., additional, Müller, L., additional, Preglej, T., additional, Heinz, L., additional, Simader, E., additional, Göschl, L., additional, Puchner, S., additional, Weiss, S., additional, Superi-Furga, G., additional, Smolen, J. S., additional, Steiner, G., additional, Aletaha, D., additional, Kiener, H., additional, Tosevska, A., additional, Karonitsch, T. M., additional, and Bonelli, M., additional

Published
2023
Full Text
View/download PDF

9. AB0402 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH EU-APPROVED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, TWO-ARM, SINGLE-DOSE STUDY IN HEALTHY SUBJECTS

Author

Yu, K. S., primary, Kim, B., additional, Shin, D., additional, Park, M. K., additional, Hwang, J. G., additional, Kim, M., additional, Chung, H., additional, Ghim, J., additional, Chung, J. Y., additional, Smolen, J. S., additional, Burmester, G. R., additional, Kim, S. H., additional, Bae, Y., additional, Jeon, D., additional, Yang, G., additional, Yoo, J., additional, Bae, J., additional, and Keystone, E., additional

Published
2023
Full Text
View/download PDF

10. POS0714 TREAT-TO-TARGET RECOMMENDATIONS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA

Author

Dejaco, C., primary, Kerschbaumer, A., additional, Aletaha, D., additional, Bond, M., additional, Hysa, E., additional, Camellino, D., additional, Ehlers, L., additional, Abril, A., additional, Appenzeller, S., additional, Cid, M. C., additional, Dasgupta, B., additional, Duftner, C., additional, Grayson, P., additional, Hellmich, B., additional, Hocevar, A., additional, Kermani, T., additional, Matteson, E., additional, Mollan, S., additional, Neill, L., additional, Ponte, C., additional, Salvarani, C., additional, Sattui, S. E., additional, Schmidt, W. A., additional, Seo, P., additional, Smolen, J., additional, Thiel, J., additional, Toro Gutiérrez, C., additional, Whitlock, M., additional, and Buttgereit, F., additional

Published
2023
Full Text
View/download PDF

13. POS0847 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY

Author

Smolen, J. S., primary, Emery, P., additional, Rigby, W., additional, Tanaka, Y., additional, Ignacio Vargas, J., additional, Damjanov, N., additional, Jain, M., additional, Kato, K., additional, Carter, K., additional, Khan, N., additional, Camp, H., additional, and Cohen, S. B., additional

Published
2023
Full Text
View/download PDF

14. POS0559 ACCELERATED WANING OF HUMORAL IMMUNE RESPONSE TO A THIRD COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

Author

Mrak, D., primary, Kartnig, F., additional, Sieghart, D., additional, Simader, E., additional, Radner, H., additional, Mandl, P., additional, Göschl, L., additional, Hofer, P., additional, Deimel, T., additional, Gessl, I., additional, Kain, R., additional, Winkler, S., additional, Smolen, J. S., additional, Perkmann, T., additional, Haslacher, H., additional, Aletaha, D., additional, Heinz, L., additional, and Bonelli, M., additional

Published
2023
Full Text
View/download PDF

16. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

Author

Furst, Daniel E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, JWJ, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, and Mease, P J

Abstract

As in previous years, the consensus group to consider the use of biological agents was constituted by rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with other Universities in the USA, Canada, and Europe. Pharmaceutical industry support was obtained from a number of companies, but these institutions had no part in the decisions about the specific programme or about the academic participants at this conference. The perspective of this consensus is from the treating physician’s point of view. The 128 rheumatologists and bioscientists who attended the consensus conference were chosen from a worldwide group of physicians and other scientists from 20 countries with expertise in the use of biological agents for the treatment of rheumatic diseases. The number of attendees and participants were limited so that not everyone who might have been interested could be invited. Additional information has come to light in the past year, corroborating the major positive effect these drugs have had in rheumatoid arthritis (RA) and other rheumatic diseases, as well as further documenting adverse events. Therefore an update of the previous consensus statement1 is appropriate. The consensus statement is annotated to document the credibility of the data supporting it as much as possible. This annotation is that of Shekelle et al2 and is described in appendix 3. As the number of possible references has become so large, sometimes reviews were used and, if they contained category A references, will be referred to as category A evidence. All participants reviewed relevant clinical published articles relating to tumour necrosis factor (TNF) and interleukin (IL)-1 blocking agents. They were given a draft consensus statement and were asked to revise the document in small discussion groups; open discussion of the revisions led to a final document, representing this updated consensus statement.

Published
2004

19. Entzündliche Gelenkerkrankungen

Author

Kiener, H. P., Pilz, I., Dunky, A., Graninger, W., Siegmeth, W., Thumb, N., Ebner, W., Schwägerl, W., Smolen, J., Petera, P., Smolen, J. S., Kolarz, G., Klein, G., Pöllmann, G., Leeb, B. F., Sautner, J., Thumb, Norbert, editor, Bröll, Hans, editor, Czurda, Rainer, editor, Siegmeth, Walter, editor, and Smolen, Josef, editor

Published
2001
Full Text
View/download PDF

20. Medikamentöse Therapie

Author

Mayrhofer, F., Eberl, G., Peichl, P., Bröll, H., Aletaha, D., Leeb, B. F., Ebner, W., Smolen, J., Graninger, W., Hermann, J., Singer, F., Ilias, W., Tilscher, H., Dunky, A., Wagner, E., Graninger, M., Dunky, Attila, editor, Graninger, Winfried, editor, Herold, Manfred, editor, Smolen, Josef, editor, and Wanivenhaus, Axel, editor

Published
2012
Full Text
View/download PDF

21. S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial

Author

Humrich, J, primary, Cacoub, P, additional, Rosenzwajg, M, additional, Pitoiset, F, additional, Pham, H, additional, Guidoux, J, additional, Leroux, D, additional, Vazquez, T, additional, Riemekasten, G, additional, Smolen, J, additional, Tsokos, G, additional, and Klatzmann, D, additional

Published
2022
Full Text
View/download PDF

22. POS1079 CLINICAL CHARACTERIZATION OF PRODROMAL AND VERY EARLY PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW FOR THE DEFINITION OF CLINICAL AND IMAGING SUSPICIOUS FEATURES FOR PROGRESSION TO PSORIATIC ARTHRITIS

Author

Zabotti, A., primary, De Marco, G., additional, Gossec, L., additional, Baraliakos, X., additional, Emmel, J., additional, Aletaha, D., additional, Iagnocco, A., additional, Smolen, J. S., additional, and Mcgonagle, D., additional

Published
2022
Full Text
View/download PDF

25. POS1076 OBESITY IS ASSOCIATED WITH LESS LIKELIHOOD OF REMISSION/ LOW DISEASE IN PSORIATIC ARTHRITIS, A CROSS-SECTIONAL STUDY OF 414 PATIENTS

Author

Leung, Y. Y., primary, Eder, L., additional, Orbai, A. M., additional, Coates, L., additional, De Wit, M., additional, Smolen, J. S., additional, Kiltz, U., additional, Palominos, P., additional, Cañete, J. D. D., additional, Scrivo, R., additional, Balanescu, A., additional, Dernis, E., additional, Meisalu, S., additional, Soubrier, M., additional, Kalyoncu, U., additional, and Gossec, L., additional

Published
2022
Full Text
View/download PDF

28. AB0400 A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS INTO THE SUCCESS RATE OF GLUCOCORTICOID DISCONTINUATION AFTER THEIR USE AS INITIAL BRIDGING THERAPY IN RHEUMATOID ARTHRITIS PATIENTS IN OBSERVATIONAL COHORTS AND CLINICAL TRIALS

Author

van Ouwerkerk, L., primary, Palmowski, A., additional, Nevins, I., additional, Buttgereit, F., additional, Verschueren, P., additional, Smolen, J., additional, Landewé, R. B. M., additional, Bijlsma, H., additional, Kerschbaumer, A., additional, Westhovens, R., additional, Huizinga, T., additional, Allaart, C., additional, and Bergstra, S. A., additional

Published
2022
Full Text
View/download PDF

31. POS0004 WHAT DOES WORSENING IN DAPSA DISEASE ACTIVITY CATEGORIES MEAN FOR PATIENTS WITH PSORIATIC ARTHRITIS? AN ANALYSIS OF 222 PATIENTS

Author

Sousa, M., primary, Smolen, J. S., additional, Gorlier, C., additional, de Wit, M., additional, Coates, L., additional, Kalyoncu, U., additional, Ruyssen-Witrand, A., additional, Leung, K., additional, Scrivo, R., additional, Cañete, J. d. D., additional, Palominos, P., additional, Meisalu, S., additional, Balanescu, A., additional, Kiltz, U., additional, Aydin, S., additional, Gaydukova, I., additional, Dernis, E., additional, Fautrel, B., additional, Orbai, A. M., additional, Lubrano, E., additional, and Gossec, L., additional

Published
2022
Full Text
View/download PDF

32. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

Author

Meisters, R, Putrik, P, Ramiro, S, Hifinger, M, Keszei, A, Van Eijk-Hustings, Y, Woolf, A, Smolen, J, Stamm, T, Stoffer-Marx, M, Uhlig, T, Moe, R, De Wit, M, Tafaj, A, Mukuchyan, V, Studenic, P, Verschueren, P, Shumnalieva, R, Charalambous, P, Vencovsky, J, Varvouni, M, Kull, M, Puolakka, K, Gossec, L, Gobejishvili, N, Detert, J, Sidiropoulos, P, Pentek, M, Kane, D, Scire, C, Arad, U, Andersone, D, Van De Laar, M, Van Der Helm-Van Mil, A, Gluszko, P, Cunha-Miranda, L, Berghea, F, Damjanov, N, Tomsic, M, Carmona, L, Turesson, C, Ciurea, A, Shukurova, S, Inanc, N, Verstappen, S, Boonen, A, Meisters R., Putrik P., Ramiro S., Hifinger M., Keszei A. P., Van Eijk-Hustings Y., Woolf A. D., Smolen J. S., Stamm T. A., Stoffer-Marx M., Uhlig T., Moe R. H., De Wit M., Tafaj A., Mukuchyan V., Studenic P., Verschueren P., Shumnalieva R., Charalambous P., Vencovsky J., Varvouni M., Kull M., Puolakka K., Gossec L., Gobejishvili N., Detert J., Sidiropoulos P., Pentek M., Kane D., Scire C. A., Arad U., Andersone D., Van De Laar M., Van Der Helm-Van Mil A., Gluszko P., Cunha-Miranda L., Berghea F., Damjanov N. S., Tomsic M., Carmona L., Turesson C., Ciurea A., Shukurova S., Inanc N., Verstappen S. M. M., Boonen A., Meisters, R, Putrik, P, Ramiro, S, Hifinger, M, Keszei, A, Van Eijk-Hustings, Y, Woolf, A, Smolen, J, Stamm, T, Stoffer-Marx, M, Uhlig, T, Moe, R, De Wit, M, Tafaj, A, Mukuchyan, V, Studenic, P, Verschueren, P, Shumnalieva, R, Charalambous, P, Vencovsky, J, Varvouni, M, Kull, M, Puolakka, K, Gossec, L, Gobejishvili, N, Detert, J, Sidiropoulos, P, Pentek, M, Kane, D, Scire, C, Arad, U, Andersone, D, Van De Laar, M, Van Der Helm-Van Mil, A, Gluszko, P, Cunha-Miranda, L, Berghea, F, Damjanov, N, Tomsic, M, Carmona, L, Turesson, C, Ciurea, A, Shukurova, S, Inanc, N, Verstappen, S, Boonen, A, Meisters R., Putrik P., Ramiro S., Hifinger M., Keszei A. P., Van Eijk-Hustings Y., Woolf A. D., Smolen J. S., Stamm T. A., Stoffer-Marx M., Uhlig T., Moe R. H., De Wit M., Tafaj A., Mukuchyan V., Studenic P., Verschueren P., Shumnalieva R., Charalambous P., Vencovsky J., Varvouni M., Kull M., Puolakka K., Gossec L., Gobejishvili N., Detert J., Sidiropoulos P., Pentek M., Kane D., Scire C. A., Arad U., Andersone D., Van De Laar M., Van Der Helm-Van Mil A., Gluszko P., Cunha-Miranda L., Berghea F., Damjanov N. S., Tomsic M., Carmona L., Turesson C., Ciurea A., Shukurova S., Inanc N., Verstappen S. M. M., and Boonen A.

Abstract

Objective As part of European League against Rheumatism (EULAR)/European Musculoskeletal Conditions Surveillance and Information Network, 20 user-focused standards of care (SoCs) for rheumatoid arthritis (RA) addressing 16 domains of care were developed. This study aimed to explore gaps in implementation of these SoCs across Europe. Methods Two cross-sectional surveys on the importance, level of and barriers (patients only) to implementation of each SoC (0-10, 10 highest) were designed to be conducted among patients and rheumatologists in 50 European countries. Care gaps were calculated as the difference between the actual and maximum possible score for implementation (ie, 10) multiplied by the care importance score, resulting in care gaps (0-100, maximal gap). Factors associated with the problematic care gaps (ie, gap≥30 and importance≥6 and implementation<6) and strong barriers (≥6) were further analysed in multilevel logistic regression models. Results Overall, 26 and 31 countries provided data from 1873 patients and 1131 rheumatologists, respectively. 19 out of 20 SoCs were problematic from the perspectives of more than 20% of patients, while this was true for only 10 SoCs for rheumatologists. Rheumatologists in countries with lower gross domestic product and non-European Union countries were more likely to report problematic gaps in 15 of 20 SoCs, while virtually no differences were observed among patients. Lack of relevance of some SoCs (71%) and limited time of professionals (66%) were the most frequent implementation barriers identified by patients. Conclusions Many problematic gaps were reported across several essential aspects of RA care. More efforts need to be devoted to implementation of EULAR SoCs.

Published
2020

34. Medikamentöse Therapie

Author

Mayrhofer, F., Eberl, G., Bröll, H., Aglas, F., Gretler, J., Eberl, R., Thumb, N., Chlud, K., Leeb, B., Peichl, P., Smolen, J. S., Ebner, W., Leeb, B. F., Hermann, J., Bach, M., Singer, F., Tilscher, H., Leodolter, S., Huber, J. C., Rainer, F., Pongratz, R., Thumb, Norbert, editor, Bröll, Hans, editor, Czurda, Rainer, editor, Siegmeth, Walter, editor, and Smolen, Josef, editor

Published
2001
Full Text
View/download PDF

35. Grundlagen

Author

Geringer, E.-M., Erlacher, L., Firbas, W., Zlabinger, G. J., Brune, K., Hoffmann, C., Fischer, G. F., Scherak, O., Siegmeth, W., Fric, A., Leodolter, S., Huber, J. C., Kolarz, G., Smolen, J., Thumb, N., Thumb, Norbert, editor, Bröll, Hans, editor, Czurda, Rainer, editor, Siegmeth, Walter, editor, and Smolen, Josef, editor

Published
2001
Full Text
View/download PDF

36. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force.

Author

van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., Arnaud L., Bruce I.N., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau F.A., Mosca M., Schneider M., Ward M.M., Alarcon G., Aringer M., Askenase A., Bae S.-C., Bootsma H., Boumpas D.T., Brunner H., Clarke A.E., Coney C., Czirjak L., Dorner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska M.H., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfa E., Smolen J., Teng Y.K.O., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth V.P., Zakharhova E., Aranow C., van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., Arnaud L., Bruce I.N., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau F.A., Mosca M., Schneider M., Ward M.M., Alarcon G., Aringer M., Askenase A., Bae S.-C., Bootsma H., Boumpas D.T., Brunner H., Clarke A.E., Coney C., Czirjak L., Dorner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska M.H., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfa E., Smolen J., Teng Y.K.O., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth V.P., Zakharhova E., and Aranow C.

Abstract

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.Copyright © 2021 BMJ Publishing Group. All rights reserved.

Published
2022

37. Bacterial native joint arthritis

Author

Hochberg, Marc C, Gravallese, Ellen M, Smolen, Josef S, van der Heijde, Désirée; https://orcid.org/0000-0002-5781-158X, Weinblatt, Michael E, Weisman, Michael H, Hochberg, M C ( Marc C ), Gravallese, E M ( Ellen M ), Smolen, J S ( Josef S ), van der Heijde, D ( Désirée ), Weinblatt, M E ( Michael E ), Weisman, M H ( Michael H ), Kronberger, Leo R W, Obenhuber, Tilman, Uçkay, Ilker; https://orcid.org/0000-0002-5552-0973, Hochberg, Marc C, Gravallese, Ellen M, Smolen, Josef S, van der Heijde, Désirée; https://orcid.org/0000-0002-5781-158X, Weinblatt, Michael E, Weisman, Michael H, Hochberg, M C ( Marc C ), Gravallese, E M ( Ellen M ), Smolen, J S ( Josef S ), van der Heijde, D ( Désirée ), Weinblatt, M E ( Michael E ), Weisman, M H ( Michael H ), Kronberger, Leo R W, Obenhuber, Tilman, and Uçkay, Ilker; https://orcid.org/0000-0002-5552-0973

Published
2022

38. Reaktive Arthritis

Author

Hitzelhammer, J., Smolen, J., König, Benno, editor, Reinhardt, Dietrich, editor, and Schuster, Hans-Peter, editor

Published
2000
Full Text
View/download PDF

41. Profil de tolérance jusqu’à 9,3 ans de baricitinib dans le traitement de la polyarthrite rhumatoïde : mise à jour d’une analyse intégrée de la tolérance

Author

Taylor, P.C., primary, Takeuchi, T., additional, Burmester, G.R., additional, Durez, P., additional, Smolen, J., additional, Deberdt, W., additional, Xie, L., additional, Zhong, J., additional, Torres, J.R., additional, Bello, N., additional, Winthrop, K., additional, and Combe, B., additional

Published
2021
Full Text
View/download PDF

43. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Author

Gossec, L, Smolen, J S, Ramiro, S, de Wit, M, Cutolo, M, Dougados, M, Emery, P, Landewé, R, Oliver, S, Aletaha, D, Betteridge, N, Braun, J, Burmester, G, Cañete, J D, Damjanov, N, FitzGerald, O, Haglund, E, Helliwell, P, Kvien, T K, Lories, R, Luger, T, Maccarone, M, Marzo-Ortega, H, McGonagle, D, McInnes, I B, Olivieri, I, Pavelka, K, Schett, G, Sieper, J, van den Bosch, F, Veale, D J, Wollenhaupt, J, Zink, A, and van der Heijde, D

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results